^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    HDP-103

    i
    Other names: HDP-103, PSMA-ATAC, Anti-PSMA antibody-targeted amanitin conjugate, PSMA ATAC, Anti-PSMA ATAC
    Associations

    News

    Trials
    Company:
    Heidelberg Pharma, Huadong Medicine
    Drug class:
    PSMA-targeted antibody-drug conjugate, RNA polymerase 2 inhibitor
    Related drugs:
    Associations

    News

    Trials
    3years
    [VIRTUAL] Combination of antibody-targeted amanitin conjugates (ATAC) with immune checkpoint inhibitors shows synergistic therapeutic effect in vitro and in vivo (AACR 2021)
    Antibody-targeted amanitin conjugates (ATACs) induced immunogenic cell death in vitro and resulted in an increased anti-tumor effect in combination with an immune checkpoint inhibitor in a subcutaneous CDX model if human PBMCs were present.Consequently, the data presented provide a rationale to the use of ATACs in combination therapy with immune checkpoint inhibitors.
    Preclinical • Checkpoint inhibition • IO biomarker
    |
    HMGB1 (High Mobility Group Box 1) • CALR (Calreticulin)
    |
    HDP-103